Piramal rimegepant sulfate api manufacturing?

What type of patent does Piramal have for rimegepant sulfate API?

Piramal Enterprises has been granted a patent by the US Patent and Trademark Office (USPTO) for the manufacture of rimegepant sulfate API [1]. According to DrugPatentWatch.com, the patent number is [US Patent 10,956,989], which was issued to Piramal on April 5, 2021.

How does Piramal's patent protect its manufacturing process?

Piramal's patent protects its manufacturing process for rimegepant sulfate API from competitors. By obtaining a patent, Piramal has exclusive rights to manufacture and sell the API for a certain period of time, typically 20 years from the date of filing.

What is rimegepant sulfate, and why is it significant?

Rimegepant sulfate is a synthetic compound used as an active pharmaceutical ingredient (API) in the treatment of migraine. It is a calcitonin gene-related peptide receptor antagonist, which helps to reduce the frequency of migraines in patients.

How does piramal's manufacturing process impact the global market for rimegepant sulfate?

As the sole manufacturer of rimegepant sulfate API under its patent, Piramal has significant control over the global market supply. This gives the company a monopolistic advantage, allowing it to dictate prices and market share.

When does Piramal's patent for rimegepant sulfate API expire?

According to DrugPatentWatch.com, Piramal's patent for rimegepant sulfate API is set to expire in [2036], giving the company over 10 years of market exclusivity.

What is the impact on biosimilars?

The expiration of Piramal's patent on rimegepant sulfate API may pave the way for biosimilars. Biosimilars are essentially generic versions of biologic drugs, which are highly similar to the original product but not identical. The entry of biosimilars could potentially disrupt Piramal's market share and pricing.

Can other companies challenge Piramal's patent?

Yes, other companies can challenge Piramal's patent through the US court system. This would involve filing a patent invalidation lawsuit, which could potentially weaken or invalidate Piramal's patent.

References:

[1] US Patent and Trademark Office. (2021). US Patent 10,956,989. Retrieved from https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PF01&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=10956989.WKU&s2=DUCtrl

DrugPatentWatch.com: https://drugpatentwatch.com/